APA (7th ed.) Citation

Wildiers, H., Armstrong, A., Cuypere, E., Dalenc, F., Dirix, L., Chan, S., . . . Triebel, F. (2024). Paclitaxel plus Eftilagimod Alpha, a soluble LAG-3 protein, in metastatic, HR+ breast cancer: Results from AIPAC, a randomized, placebo controlled phase IIb trial. Clinical cancer research, 30(3), . https://doi.org/10.1158/1078-0432.CCR-23-1173

Chicago Style (17th ed.) Citation

Wildiers, Hans, et al. "Paclitaxel Plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial." Clinical Cancer Research 30, no. 3 (2024). https://doi.org/10.1158/1078-0432.CCR-23-1173.

MLA (9th ed.) Citation

Wildiers, Hans, et al. "Paclitaxel Plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial." Clinical Cancer Research, vol. 30, no. 3, 2024, https://doi.org/10.1158/1078-0432.CCR-23-1173.